一项评估 iTind 与 UroLift 相比安全性的随机国际研究 (MT-08)
一项上市后、前瞻性、随机、对照、多中心国际研究,以评估临时植入镍钛合金装置 (iTind) 与 UroLift® 系统在有症状良性前列腺增生症 (BPH) 受试者中的安全性
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
研究概览
详细说明
Both iTind and UroLift are minimally invasive treatment options for relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The iTind device is a temporary, self-expanding nitinol implant that remains in place for 5 to 7 days to reshape the prostatic urethra through localized ischemic pressure and tissue remodeling. In contrast, the UroLift system involves the permanent placement of transprostatic implants that retract the enlarged lateral lobes of the prostate to widen the urethral lumen.
This study is designed to directly compare the safety and effectiveness of the iTind device versus the UroLift system in treating LUTS due to BPH.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Melanie Bonds, MS
- 电话号码:+1-703-851-4615
- 邮箱:Melanie.Bonds@olympus.com
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 招聘中
- Mayo Clinic Arizona
-
首席研究员:
- Mitchell Humphreys, MD
-
接触:
- Rev Vilasan Shylaja
- 电话号码:480-574-1466
- 邮箱:VilasanShylaja.Revathy@mayo.edu
-
Tucson、Arizona、美国、85704
- 终止
- Arizona Urology Specialists
-
-
California
-
Fresno、California、美国、93720
- 招聘中
- Urology Associates of Central California
-
首席研究员:
- William Schiff, MD
-
接触:
- Joe Vidal
- 电话号码:559-321-2919 559-720-3646
- 邮箱:jvidal@urologyassociates.net
-
Sacramento、California、美国、95823
- 招聘中
- Golden State Urology
-
首席研究员:
- Prithipal Sethi, MD
-
接触:
- Sehaj Sethi
- 电话号码:308 916-245-8888
- 邮箱:ssethi@goldenstateurology.com
-
-
Illinois
-
Evanston、Illinois、美国、60201
- 终止
- NorthShore University Health System Research Institute
-
-
Louisiana
-
New Orleans、Louisiana、美国、70119
- 主动,不招人
- Southeast Louisiana Veterans Health Care System
-
-
Minnesota
-
Woodbury、Minnesota、美国、55125
- 撤销
- Minnesota Urology
-
-
Nebraska
-
Omaha、Nebraska、美国、68124
- 招聘中
- The Urology Center
-
首席研究员:
- Sida Niu, MD
-
接触:
- Amy Nelson
- 电话号码:402-397-7989
- 邮箱:anelson@adultpediatricuro.com
-
-
Nevada
-
Las Vegas、Nevada、美国、89121
- 招聘中
- Pacific West Urology
-
接触:
- John Dull
- 电话号码:702-321-8045
- 邮箱:john.dull@pacificwesturology.com
-
首席研究员:
- Joel Abbott, MD
-
-
New York
-
Syosset、New York、美国、11791
- 招聘中
- Feinstein Institutes for Medical Research / Northwell Health
-
首席研究员:
- Bilal Chughtai, MD
-
接触:
- Jennifer Polo
- 电话号码:516-628-5926
- 邮箱:jpolo1@northwell.edu
-
-
Tennessee
-
Germantown、Tennessee、美国、38138
- 招聘中
- The Conrad Pearson Clinic
-
首席研究员:
- Adam Stewart, MD
-
接触:
- Jessica Parks
- 电话号码:901-464-2711
- 邮箱:jessica.parks@conradpearson.com
-
-
Texas
-
Austin、Texas、美国、78705
- 招聘中
- Midtown Urology Associates
-
首席研究员:
- Tyler McClintock, MD
-
接触:
- Andrew Barger
- 电话号码:512-451-7935
- 邮箱:APBarger@cimplify.net
-
Houston、Texas、美国、77027
- 招聘中
- Houston Metro Urology
-
接触:
- Lena Ellis
- 电话号码:713-634-4405
- 邮箱:lena.ellis@hmutx.com
-
首席研究员:
- Mark Sutton, MD
-
San Antonio、Texas、美国、78240
- 招聘中
- The Urology Place
-
首席研究员:
- Naveen Kella, MD
-
接触:
- Raji Thiruppathiraj
- 电话号码:210-617-3670
- 邮箱:raji@theupi.com
-
-
Virginia
-
Alexandria、Virginia、美国、22311
- 招聘中
- Potomac Urology Center
-
首席研究员:
- Nilay Gandhi, MD
-
接触:
- Chamin Lim
- 电话号码:423 703-680-2111
- 邮箱:clim@potomacurology.com
-
-
-
-
-
Dunfermline、英国、KY12 0SU
- 招聘中
- Queen Margaret Hospital
-
首席研究员:
- Feras Al Jaafari, MD
-
接触:
- Keith Boath
- 电话号码:20951 +44-1383-623623
- 邮箱:Keith.boath@nhs.scot
-
London、英国、GU16 7UJ
- 招聘中
- Frimley Park Hospital
-
首席研究员:
- Neil Barber, MD
-
接触:
- Reynette Baroman
- 邮箱:r.baroman@nhs.net
-
Norwich、英国、NR4 7UY
- 招聘中
- Norfolk & Norwich University Hospital
-
首席研究员:
- Mark Rochester, MD
-
接触:
- Catherine Rennie
- 电话号码:+44-1603 646105
- 邮箱:catherine.rennie@nnuh.nhs.uk
-
-
Middlesex
-
Isleworth、Middlesex、英国、TW7 6AF
- 招聘中
- Chelsea and Westminster Hospital
-
首席研究员:
- Samuel Bishara, MD
-
接触:
- Farrah Akkouch
- 电话号码:+44 (0)20 321 5181
- 邮箱:chelwest.wmh.olympus@nhs.net
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended
- Willing and able to provide informed consent
- Males ≥ 50 years of age or older
- PSA < 4 ng/ml or if the PSA is 4 - 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator (PI) by local standard of care methods within prior 6 months
- Prostate volume up to 75 cc (inclusive) documented by cross-sectional imaging (TRUS, MRI, etc.). Results from standard of care imaging may be accepted up to 6 months prior to Screening
- International Prostate Symptom Score (IPSS) for urinary symptoms ≥ 13
- Maximum urinary flow rate (Qmax) of ≤ 15 mL/sec and ≥ 5 mL/sec (voided volume must be ≥ 125 mL)
- Willing and able to complete all study visits including questionnaires at baseline and at follow-up visits
Exclusion Criteria:
- History of prostate cancer or suspected, should be ruled out to the satisfaction of the PI by local standard of care methods within prior 6 months
- Confirmed bladder cancer within the last 2 years or currently suspected bladder cancer
- History of acute bacterial prostatitis within the last 2 years
- Median lobe obstruction of the prostate as confirmed by cross-sectional imaging
- PSA value > 10 ng/ml
- Contraindicated for iTind or UroLift as determined by the PI
- Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes or other neurological disorders that affect bladder function
- Clinically significant bladder diverticulum
- Diagnosed with urethral stricture, meatal stenosis, bladder neck contracture, rectal disease, artificial urinary sphincter, incompetent sphincter, urinary incontinence due to incompetent sphincter
- Prior rectal surgery (other than hemorrhoidectomy) or history of rectal disease treatment if the therapy may potentially cause injury to site (e.g., if a transrectal probe is used), pelvic radiotherapy or radical pelvic surgery, urinary diversion surgery, prostate surgery, balloon dilation, urethral stent implantation, laser prostatectomy, or any other invasive treatment to the prostate, or penile prosthesis if it may prevent insertion of the iTind or UroLift device
- An active urinary tract infection during randomization
- Clinically significant hematuria within the last 3 months or ongoing cystolithiasis
- Prostate volume > 75 cc
- Post-void residual volume (PVR) > 250 mL
- Actively using catheterization or unable to void naturally
- Unable to complete a 2-week washout period for alpha blockers prior to procedure or unable to discontinue 5ARIs or daily use of PDE5 inhibitors by the time of procedure
- Taking anti-platelet or anticoagulants (except low dose aspirin - 81 mg - 100 mg) within the last 7 days prior to procedure
- Known or suspected allergy to nickel, titanium or polyester/polypropylene
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:iTind arm
The iTind is a minimally invasive temporary implant |
The iTind is implemented for 5-7 days |
|
有源比较器:UroLift
The UroLift is a minimally invasive permanent implant |
UroLift is a minimally invasive procedure where permanent implants are placed in the prostate. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months
大体时间:3 months
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months |
3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months
大体时间:12 month
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months |
12 month
|
|
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure.
大体时间:3 month
|
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure. |
3 month
|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months
大体时间:1, 6, 24, and 36 months
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months |
1, 6, 24, and 36 months
|
|
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months
大体时间:1, 3, 6, 12, 24, and 36 months
|
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months |
1, 3, 6, 12, 24, and 36 months
|
|
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months
大体时间:1, 3, 6, 12, 18, 24, and 36 months
|
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months |
1, 3, 6, 12, 18, 24, and 36 months
|
|
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events
大体时间:1, 6, 12, 18, 24, and 36, months
|
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events |
1, 6, 12, 18, 24, and 36, months
|
合作者和调查者
调查人员
- 首席研究员:Neil Barber, MD、Frimley Park Hospital
- 首席研究员:Bilal Chughtai, MD、Northwell Health
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.